# Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients

> **NCT02226757** · PHASE2 · UNKNOWN · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 16 (estimated)

## Conditions studied

- NSCLC
- HER2-expression
- EGFR-mutation

## Interventions

- **DRUG:** Paclitaxel-trastzumab

## Key facts

- **NCT ID:** NCT02226757
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-08
- **Primary completion:** 2016-08
- **Final completion:** —
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2014-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02226757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02226757, "Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02226757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*